3 not yet recruiting, 3 recruiting, 3 unknown, 1 active not recruiting. 7 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 3, Recruiting 2, Unknown 2 |
| Phase 3 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow KN026: new trials by email Literature Review of KN026 trials Research Report on KN026
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer SYS6023, KN026 - Advanced Breast Cancer | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 36 | 2026-05-25 | 2026-06-16 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer KN026, Capecitabine, Enlonstobart - HER2-positive Gastric Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 490 | 2025-12-30 | 2026-01-12 |
| JSKN003 Combined Treatment of HER2-positive Gastric Cancer JSKN003, KN026, Capecitabine - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 153 | 2025-06-15 | 2025-05-31 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer KN026, HB1801, Pertuzumab - Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Shanghai JMT-Bio Inc. | 520 | 2024-12-16 | 2026-07-07 |
| Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC KN026, KN046, XELOX - HER2-positive Locally Advanced Resectable Gastric Cancer | Phase 2 | Recruiting | Peking University | 18 | 2023-09-22 | 2024-05-10 |
| KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma KN026, KN046, XELOX - HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 80 | 2023-08-15 | 2023-08-21 |
| Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer KN026 - Breast Cancer | Phase 2 | Unknown | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 30 | 2021-08-09 | 2022-06-22 |
| Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer Concurrent chemotherapy and KN026, KN026 monotherapy, KN026 combination - Metastatic Breast Cancer | Phase 2 | Unknown | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 68 | 2019-12-31 | 2023-09-21 |
| KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer KN026 - Breast Cancer, Gastric/Gastroesophageal Junction Cancer | Phase 1 | Unknown | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 22 | 2019-06-18 | 2021-11-17 |
| Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer KN026 - Breast Cancer, Gastric Cancer | Phase 1 | Completed | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 63 | 2018-09-17 | 2024-03-12 |
Breast Neoplasms (4) · Stomach Neoplasms (1)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd (4) · Shanghai JMT-Bio Inc. (4) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Peking University (1) · Peking University Cancer Hospital & Institute (1)
China (8) · United States (1)
Jiong Wu, professor (1) · Qingyuan Zhang, M.D. (1) · Qingyuan Zhang, Professor (1)